Skip to search formSkip to main contentSkip to account menu

KMUP 1

Known as: KMUP-1, KMUP1 cpd 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Phosphodiesterase (PDE) inhibitors have been suggested as a possible candidate for the treatment of osteopenia, including… 
2010
2010
Background and purpose:  KMUP‐1 is known to increase cGMP, enhance endothelial nitric oxide synthase (eNOS) and suppress Rho… 
2010
2010
Background and purpose:  To determine whether KMUP‐1, a novel xanthine‐based derivative, attenuates isoprenaline (ISO)‐induced… 
2009
2009
KMUP‐1 has been suggested to be beneficial in the treatment of benign prostatic hyperplasia. This study is aimed to further… 
2007
2007
Soluble guanylyl cyclase (sGC)/cyclic guanosine monophosphate (cGMP)/protein kinase G (PKG) and Rho kinase (ROCK2) pathways are… 
2006
2006
In the study of anti-proinflammation by 7-[2-[4-(2-chlorobenzene)piperazinyl] ethyl]-1,3-dimethylxanthine (KMUP-1) and 7-[2-[4-(4… 
2005
2005
This study investigated whether KMUP‐1, a synthetic xanthine‐based derivative, augments the delayed‐rectifier potassium (KDR)‐ or… 
2004
2004
7‐[2‐[4‐(2‐chlorophenyl)piperazinyl]ethyl]‐1,3‐dimethylxanthine (KMUP‐1) produces tracheal relaxation, intracellular accumulation… 
2002
2002
In isolated endothelium‐intact or denuded rabbit corpus cavernosum preconstricted with phenylephrine, KMUP‐1 (0.001 – 10 μM… 
Highly Cited
2001
Highly Cited
2001
KMUP‐1 (1, 3, 5 mg kg−1, i.v.), a xanthine derivative, produced dose‐dependent sustained hypotensive and short‐acting…